Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years
- 31 January 2009
- journal article
- research article
- Published by Elsevier in Journal of Adolescent Health
- Vol. 44 (1) , 33-40
- https://doi.org/10.1016/j.jadohealth.2008.10.002
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Chapter 2: The burden of HPV-related cancersVaccine, 2006
- Vaccination as a prevention strategy for human papillomavirus-related diseasesJournal of Adolescent Health, 2005
- A Longitudinal Study of Genital Human Papillomavirus Infection in a Cohort of Closely Followed Adolescent WomenThe Journal of Infectious Diseases, 2005
- Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective studyBritish Journal of Cancer, 2002
- Human Papillomavirus Infection as a Risk Factor for Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2001
- Type-Specific Persistence of Human Papillomavirus DNA before the Development of Invasive Cervical CancerNew England Journal of Medicine, 1999
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999
- Human Papillomaviruses and Anogenital CancersNew England Journal of Medicine, 1997
- Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancerJNCI Journal of the National Cancer Institute, 1997
- Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control studyBMJ, 1996